Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

18.54
-0.7300-3.79%
Post-market: 18.540.00000.00%19:14 EDT
Volume:581.56K
Turnover:10.76M
Market Cap:535.29M
PE:-100.50
High:19.36
Open:19.12
Low:18.08
Close:19.27
Loading ...

BRIEF-Castle Biosciences To Acquire Previse

Reuters
·
06 May

Castle Biosciences Q1 EPS $(0.20) Misses $(0.07) Estimate, Sales $88.00M Beat $80.38M Estimate

Benzinga
·
06 May

BRIEF-Castle Biosciences Q1 Basic EPS USD -0.9

Reuters
·
06 May

Castle Biosciences Inc - Q1 Adj EPS $-0.20

THOMSON REUTERS
·
06 May

Castle Biosciences Q1 Revenue USD 87.988 Million VS. Ibes Estimate USD 80.3 Million

THOMSON REUTERS
·
06 May

Castle Biosciences Inc Outlook FY REV $287 Mln - 297 Mln

THOMSON REUTERS
·
06 May

Castle Biosciences Reports First Quarter 2025 Results

GlobeNewswire
·
06 May

Castle Biosciences to Acquire Previse

THOMSON REUTERS
·
06 May

Castle Biosciences Inc: Terms of Agreement Are Undisclosed.

THOMSON REUTERS
·
06 May

Castle Biosciences to Acquire Previse

GlobeNewswire
·
06 May

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

GlobeNewswire
·
01 May

Castle Biosciences' DecisionDx-Melanoma Test Orders Reach 200,000

MT Newswires Live
·
29 Apr

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

GlobeNewswire
·
26 Apr

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

GlobeNewswire
·
08 Apr

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

GlobeNewswire
·
07 Apr

Are Castle Biosciences, Inc.'s (NASDAQ:CSTL) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Simply Wall St.
·
02 Apr

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

GlobeNewswire
·
29 Mar

Castle Biosciences Inc : Guggenheim Cuts Target Price to $30 From $37

THOMSON REUTERS
·
28 Mar

BTIG Keeps Their Buy Rating on Castle Biosciences (CSTL)

TIPRANKS
·
18 Mar

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Business Wire
·
07 Mar